The LRI is the country’s only nonprofit organization singularly devoted to novel research in lupus.
We champion innovation, scientific creativity, and the highest-caliber science in our relentless hunt for answers on lupus.
We enable investigators to pursue bold yet sound scientific hypotheses in lupus.
And it's working.
Founded and funded by families, shaped by scientists.
What We Fund
- Novel ideas on why and how lupus happens—and how to stop it. Learn more by choosing a topic from the list at right.
- Unlike federal agencies and other research organizations, we do not require extensive preliminary data to qualify for a grant.
- What does matter in the rigorous scientific review: innovation, scientific quality, potential for success. Read about the LRI's Unique Approach
- Novel research on the biology of human lupus—using human tissue to break through to discoveries directly relevant to humans. Read more
With prevention, new treatments, and a cure the goal, we also:
- work intensively with industry in moving basic discoveries to clinical trials.
- take advantage of new cutting-edge technologies in systems biology to rapidly accelerate the pace of lupus discovery—a whole new way of looking at lupus.
To date, we've awarded 85 Novel Research grants.
- Recipients are at 55 academic and medical centers across the nation.
- Each $300,000 award is given over the course of 3 years.
LRI scientists have made breakthroughs in:
- Genes that increase susceptibility to lupus
- How lupus damages organs—kidneys, heart, brain, skin
- Pathways that enable misguided antibodies to attack
- Molecules that determine control of the immune system
- Targets for new treatments
- Biomarkers for diagnosing, monitoring and treating lupus
Of the LRI’s $30 million invested so far, millions more have been secured at the NIH and other agencies to expand on the research.
LRI scientists have been successful:
- in leveraging millions for lupus research. Read more
- in changing what is known about lupus. Read more
Without the LRI, these findings would very likely not exist.
—William E. Paul, MD
Chief, Laboratory of Immunology at NIH-NIAID
CKChair, LRI Scientific Advisory Board